http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4115885-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eab56e4fe8837840887f41af83e328ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b938e146229db0980a37904b361ea3d4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate | 2021-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3c6ab7c63940395bc17a18218fd469d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34886d4dba0ff2d7156326105c279e50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05652bd49306a2d421c446973d2b0f1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac04c4e4a8c2d66a7663f07c242fb454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce44623e21c3f9d630f9cd54f1f80a1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b23460e57b2f29d22a6a83377d83ee2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd9adaf26717455ecffcbff8677395f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d800edc119d52e2df6ce4971c00416f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4b9f96824df8d0b192c7e48d6944619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d668e782897445b20ee905a37db91410 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbb68b31a426e1c117f5eafd87879f34 |
| publicationDate | 2023-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-4115885-A1 |
| titleOfInvention | A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation |
| abstract | The invention relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof for use in the treatment and/or prevention of a medical condition associated with a viral infection and comprising hyperinflammation in a human subject. The invention further relates to a combination of BAY 86-5277 or a salt thereof and at least one other treatment, such as a guideline treatment for severe respiratory disease, for example recommended by the S3 guideline on in-patient treatment of COVID-19, preferably a glucocorticoid, more preferably dexamethasone. The invention further relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof or said combination with a glucocorticoid, and use of the combination or composition, in the treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with hyperinflammation, preferably hyperinflammation in the respiratory tract, acute respiratory failure, pneumonia, acute respiratory distress syndrome and/or multiorgan failure. In preferred embodiments, the invention relates to the treatment and/or prevention of a medical condition associated with a SARS-CoV infection, preferably SARS-CoV-2 infection. |
| priorityDate | 2021-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 828.